MedTrace Logo

68Ga-NTA-476 Imaging in Prostate Cancer

NCT06520449 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2025-09-25

No results posted yet for this study

Summary

This study is investigating a new agent to be used in PET imaging for prostate cancer, called 68Ga-NTA-476. It aims to find out where 68Ga-NTA-476 goes in the body once it is injected into a person and whether there are any side effects or issues with tolerating the compound. This will be compared to an existing imaging compound which is currently used in Australia called 18F-DCFPyl. 68Ga-NTA-476 has been developed and tested in the laboratory; however, this is the first time that it will be tested in humans.

Conditions

Interventions

DRUG

68Ga-NTA-476

The novel Prostate Specific Membrane Antigen (PSMA) targeting molecule, NTA-476, is comprised of a small peptide targeting moiety that is attached to a linker and dodecane tetraacetic acid (DOTA) cage which enables chelation of the radionuclide 68Ga for Positron Emission Tomography (PET) imaging.

Sponsors & Collaborators

  • 3B Pharmaceuticals GmbH

    collaborator INDUSTRY

  • Melbourne Theranostic Innovation Centre

    lead NETWORK

Principal Investigators

  • Prof.Rod Hicks, MB BS, MD, FRACP, FICIS · Melbourne Theranostic Innovation Centre

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-09-13
Primary Completion
2024-12-12
Completion
2025-01-17

Countries

  • Australia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06520449 on ClinicalTrials.gov